下一个

自动播放

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 意见 • 07/14/23
分享
嵌入
administrator
administrator
订户
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放